Roffman Miller Associates Increased Bank Of America (BAC) Stake; Profile of 9 Analysts Covering Seres Therapeutics, Inc. (MCRB)

May 18, 2018 - By Henry Gaston

Seres Therapeutics, Inc. (NASDAQ:MCRB) Logo

Roffman Miller Associates Inc increased Bank Of America Corp (BAC) stake by 65.29% reported in 2017Q4 SEC filing. Roffman Miller Associates Inc acquired 92,005 shares as Bank Of America Corp (BAC)’s stock declined 1.20%. The Roffman Miller Associates Inc holds 232,932 shares with $6.88 million value, up from 140,927 last quarter. Bank Of America Corp now has $310.32B valuation. The stock decreased 0.67% or $0.205 during the last trading session, reaching $30.605. About 19.86 million shares traded. Bank of America Corporation (NYSE:BAC) has risen 28.18% since May 18, 2017 and is uptrending. It has outperformed by 16.63% the S&P500.




Among 9 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics Inc had 26 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Monday, January 25. Canaccord Genuity initiated the stock with “Buy” rating in Wednesday, July 22 report. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) earned “Buy” rating by Cantor Fitzgerald on Thursday, March 8. The stock has “Outperform” rating by Leerink Swann on Tuesday, July 21. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, October 19. Cantor Fitzgerald maintained the shares of MCRB in report on Wednesday, August 30 with “Buy” rating. Bank of America upgraded the shares of MCRB in report on Thursday, October 22 to “Buy” rating. The rating was initiated by Bank of America on Tuesday, July 21 with “Neutral”. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) earned “Buy” rating by H.C. Wainwright on Friday, August 4. Oppenheimer maintained the stock with “Buy” rating in Tuesday, March 20 report. See Seres Therapeutics, Inc. (NASDAQ:MCRB) latest ratings:

10/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0000 Maintain
20/03/2018 Broker: Oppenheimer Rating: Buy Maintain
08/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
11/01/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0 Maintain

The stock decreased 1.80% or $0.15 during the last trading session, reaching $8.2. About 36,728 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 31.05% since May 18, 2017 and is downtrending. It has underperformed by 42.60% the S&P500.

More recent Seres Therapeutics, Inc. (NASDAQ:MCRB) news were published by: Seekingalpha.com which released: “Seres Therapeutics’ (MCRB) CEO Roger Pomerantz on Q1 2018 Results – Earnings Call Transcript” on May 13, 2018. Also Businesswire.com published the news titled: “Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and …” on May 07, 2018. Businesswire.com‘s news article titled: “Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates” with publication date: May 09, 2018 was also an interesting one.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $333.35 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

Among 33 analysts covering Bank of America (NYSE:BAC), 22 have Buy rating, 0 Sell and 11 Hold. Therefore 67% are positive. Bank of America had 114 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was upgraded by Macquarie Research to “Underperform” on Tuesday, August 25. The firm has “Neutral” rating given on Tuesday, November 15 by Guggenheim. On Tuesday, July 18 the stock rating was maintained by BMO Capital Markets with “Hold”. The firm earned “Buy” rating on Friday, August 11 by Jefferies. The firm has “Overweight” rating by Morgan Stanley given on Friday, February 2. On Friday, October 6 the stock rating was maintained by BMO Capital Markets with “Hold”. The stock has “Buy” rating by Nomura on Monday, April 16. Citigroup downgraded the stock to “Neutral” rating in Tuesday, April 4 report. The firm has “Hold” rating by BMO Capital Markets given on Wednesday, April 12. The firm earned “Buy” rating on Tuesday, June 6 by Keefe Bruyette & Woods.

Bank of America Corporation (NYSE:BAC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: